{
    "clinical_study": {
        "@rank": "58889", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "Budesonide granules 9 mg"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo granules"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of\n      active incomplete microscopic colitis."
        }, 
        "brief_title": "Budesonide for Induction of Remission in Incomplete Microscopic Colitis", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Incomplete Microscopic Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Microscopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "N.A."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically established diagnosis of incomplete microscopic colitis (MCi)\n\n          -  History of chronic non-bloody, watery diarrhoea\n\n          -  Clinically active disease\n\n        Exclusion Criteria:\n\n          -  Other significant abnormalities in colonoscopy\n\n          -  Infectious cause of diarrhoea\n\n          -  Clinical suspicion of drug-induced diarrhoea\n\n          -  Prior and present MC\n\n          -  History of bowel resection\n\n          -  Radiation therapy of the abdominal or pelvic region\n\n          -  Positive antibody titres for celiac disease\n\n          -  Untreated active thyroid dysfunction\n\n          -  Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder\n             reducing life expectancy\n\n          -  Abnormal hepatic function\n\n          -  Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease,\n             glaucoma, cataract, or infection if careful medical monitoring is not ensured\n\n          -  History of colorectal cancer\n\n          -  History of cancer (other than colorectal) in the last 5 years\n\n          -  Therapy with immunomodulators/budesonide or other\n             steroids/antibiotics/anti-diarrhoeal drugs\n\n          -  Current or intended pregnancy or breast-feeding\n\n          -  Doubt about the patient's cooperation, e.g. because of addiction to alcohol or drugs\n\n          -  Participation in another clinical trial within the last 30 days, simultaneous\n             participation in another clinical trial, or previous participation in this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142634", 
            "org_study_id": "BUG-3/MIC", 
            "secondary_id": "2013-001912-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "description": "per day", 
                "intervention_name": "Budesonide granules 9 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "description": "per day", 
                "intervention_name": "Placebo granules", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Budesonide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "prof.miehlke@mdz-hamburg.de", 
                    "last_name": "Stephan Miehlke, MD", 
                    "phone": "+49 40 460", 
                    "phone_ext": "2001"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20249"
                    }, 
                    "name": "Centre for Digestive Diseases"
                }, 
                "investigator": {
                    "last_name": "Stephan Miehlke, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andreas.munch@lio.se", 
                    "last_name": "Andreas M\u00fcnch, MD", 
                    "phone": "+46 101030000"
                }, 
                "facility": {
                    "address": {
                        "city": "Link\u00f6ping", 
                        "country": "Sweden", 
                        "zip": "58185"
                    }, 
                    "name": "University Hospital of Link\u00f6ping, Dept. of Gastroenterology and Hepatology"
                }, 
                "investigator": {
                    "last_name": "Andreas M\u00fcnch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis", 
        "overall_contact": {
            "email": "mohrbacher@drfalkpharma.de", 
            "last_name": "Ralf Mohrbacher, MSc", 
            "phone": "+49 761 1514", 
            "phone_ext": "156"
        }, 
        "overall_contact_backup": {
            "email": "greinwald@drfalkpharma.de", 
            "last_name": "Roland Greinwald, PhD", 
            "phone": "+49 761 1514", 
            "phone_ext": "0"
        }, 
        "overall_official": {
            "affiliation": "University Hospital of Link\u00f6ping, Dept. of Gastroenterology and Hepatology", 
            "last_name": "Andreas M\u00fcnch, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of clinical remission", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142634"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of clinical remission", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Rate of clinical remission", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Time to remission", 
                "safety_issue": "No", 
                "time_frame": "N.A."
            }, 
            {
                "measure": "Number of formed/soft/watery stools per week", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Number of days with abdominal pain", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Number of days with urgency", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Rate of histological remission", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Physician's global assessment at final visit", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Dr. Falk Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Falk Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}